About Vertex Pharmaceuticals
Vertex Pharmaceuticals is a publicly listed company based in United States founded in 1989 by Joshua Boger. Developer of drugs for the treatment of multiple disorders. The company has 6,100 employees. Vertex Pharmaceuticals has completed 5 acquisitions, including Alpine Immune Sciences, Crinetics and Exonics. Its chief executive, as recorded, is Reshma Kewalramani. Its website vrtx.com draws about 342 thousand monthly visits. Vertex Pharmaceuticals offers products and services including Cystic Fibrosis Medicines, Kidney Disease Treatments, and Clinical Trial Programs. Its focus areas include Diversified Pharmaceuticals and Drugs. Its legal entity in India is Vertex Pharmaceuticals Ltd (U24232MP1984PLC002622). Its competitors include Roivant Sciences, AbbVie and Gilead; 1 of its 3 listed competitors has raised funding.
Company details
Vertex Pharmaceuticals was founded in 1989 in the United States. Operations focus on the biotechnology sector, where small molecule drugs are developed to address cystic fibrosis, viral diseases, inflammation, autoimmune conditions, cancer, and pain. Treatments such as IVACAFTOR and LUMACAFTORIVACAFTOR target the CFTR protein by enhancing channel opening and preventing misfolding. In 2022, annual revenues reached 8.93 billion, with net profit at 3.32 billion.
- Annual Revenue$12.07 B (USD)9.92as on Dec 31, 2025
- Net Profit$3.95 B (USD)as on Dec 31, 2025
- EBITDA$4.97 B (USD)8.82as on Dec 31, 2025
- Latest Funding Round$350K (USD), Grant
Feb 2010
- InvestorsHHS
& 1 more
- Employee Count6,100
- Investments & AcquisitionsAlpine Immune Sciences
& 4 more
Associated legal entities of Vertex Pharmaceuticals
Vertex Pharmaceuticals operates through Vertex Pharmaceuticals Ltd (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Ltd CIN U24232MP1984PLC002622 | Active | 22 Oct 1984 | Indore, Madhya Pradesh | View details |
Products & Services of Vertex Pharmaceuticals
Vertex Pharmaceuticals offers a comprehensive portfolio of products and services, including Cystic Fibrosis Medicines, Kidney Disease Treatments, and Clinical Trial Programs.
Treatments targeting cystic fibrosis symptoms and progression
Medicines for APOL1-mediated kidney diseases
Platforms for testing new medicines in trials
Apps and channels of Vertex Pharmaceuticals
its YouTube channel Vertex Pharmaceuticals has 3.1K subscribers and 30 videos.
Videos from Vertex Pharmaceuticals
The most watched videos on Vertex Pharmaceuticals's YouTube channel, Vertex Pharmaceuticals (3.1K subscribers). Click a video to play it here.
More on Vertex Pharmaceuticals.
Funding Insights of Vertex Pharmaceuticals
- Total Rounds 7
- Last Round Grant — $350,000
- First Round $15M
(Nov 1994)
- Investors Count 2
All 7 funding rounds of Vertex Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
2 investors in total: 2 institutional.
Investors in Vertex Pharmaceuticals
Vertex Pharmaceuticals has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include HHS and Athyrium Capital Management.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Global private equity investments are managed by the firm. | athyrium.com | New York, United States | ||
Public health and human services are overseen by HHS. | 1953 | hhs.gov |
Investor details for Vertex Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Vertex Pharmaceuticals
996 people are tracked at Vertex Pharmaceuticals (491 in leadership, 9 in board & advisors, 496 in team); the tracked headcount is 6,100.
| Name | Role | Group |
|---|---|---|
Joshua Boger | Founder | Leadership |
Reshma Kewalramani | CEO | Leadership |
Ransi Somaratne M.D. | Senior Vice President | Leadership |
John Jorden | Vice President Finance | Leadership |
William T. | Associate Director Of Global Facilities Engineering | Leadership |
Bethany Rossi | Vice President, Organization Development & Culture | Leadership |
Charles F. Wagner | EVP, CFO | Leadership |
Vincent Shih | Director, Biomarkers And Imaging | Leadership |
Partha Ray | Director– Business Development | Leadership |
Michael Kairiss | Associate Director, Business Development | Leadership |
Tarik Monteiro | Product Quality Director | Leadership |
Jamie Maskwa | Associate Director - Commercial Supply Chain | Leadership |
Jessica Drake | Director - Project Management & Strategic Operations, Office Of The CEO | Leadership |
Laura Zelazoski | Director, Clinical Scientist | Leadership |
Nathan Etessami | Sr. Director, Early Pipeline Commercial Strategy | Leadership |
Sophie N. | Director, Project Management And Strategic Operations VCGT | Leadership |
Jessica Geiger | Associate Director, Health Economics And Outcomes Research | Leadership |
Aaron Kraus | Sr. Director, HRBP For Technology And Data Science | Leadership |
Jonathan Harty | Director, Clinical Quality & Development Operations | Leadership |
Catharine Bulik | Associate Director Of Clinical Pharmacology | Leadership |
976 more people are available in the full profile.
Complete people profiles for Vertex Pharmaceuticals
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Vertex Pharmaceuticals
Vertex Pharmaceuticals is a publicly listed company on the NASDAQ with ticker symbol VRTX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date24 Jul 1991
- Listed onNASDAQ: VRTX
- Listed entityVertex Pharmaceuticals Incorporated
- Exchange sectorHealth technology
- ISINUS92532F1003
- Share price$485.22 (-4.3% on the day) · 2026-10-13
- Market capitalisation$122.98B
- Price to earnings28.2
- EPS (diluted, trailing year)$17.19
- Volume (last session)1,187,510
Financials of Vertex Pharmaceuticals
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $12.07B | $3.95B | $4.97B |
| 2024 | $10.98B | -$535.6M | $4.57B |
| 2023 | $9.84B | $3.62B | $4.46B |
| 2022 | $8.75B | $3.32B | $4.33B |
| 2021 | $7.60B | $2.34B | $2.93B |
Balance sheet, profit and loss, cash flow and ratios of Vertex Pharmaceuticals Ltd are on its company page.
Detailed financial statements for Vertex Pharmaceuticals
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Vertex Pharmaceuticals
Vertex Pharmaceuticals has strategically engaged in corporate development activities, having acquired 5 companies. Notable acquisitions include Alpine Immune Sciences, Crinetics and Exonics.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Developer of therapies for the treatment of endocrine-related diseases and cancers | crinetics.com | San Diego, United States | 2008 | Jul 2026 | $10B | |
Developer of immunotherapies to treat cancer and autoimmune disorders | alpineimmunesciences.com | Seattle, United States | 2015 | Apr 2024 | $4.9B | |
Cell therapy for diabetes is developed from stem cells. | viacyte.com | San Diego, United States | 1999 | Jul 2022 | $320M | |
Provider of bio-artificial pancreas for Type 1 Diabetes treatment | semma-tx.com | Cambridge, United States | 2015 | Sep 2019 | $950M | |
CRISPR/Cas-9 therapies for Duchenne Muscular Dystrophy are developed. | exonicstx.com | Boston, United States | 2016 | Jun 2019 | $245M |
Complete acquisition details for Vertex Pharmaceuticals
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Vertex Pharmaceuticals
9 dated milestones of Vertex Pharmaceuticals across 37 years, from founding to its latest funding, stage changes and deals.
- Founded Vertex Pharmaceuticals is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $15.0M.
- Funding Latest funding round, Grant, of $350K.
- Acquisition Acquires Exonics.
- Acquisition Acquires Semma Therapeutics.
- Acquisition Acquires ViaCyte.
- Acquisition Acquires Alpine Immune Sciences.
- Acquisition Acquires Crinetics.
Competitors of Vertex Pharmaceuticals
Vertex Pharmaceuticals has 3 listed competitors in our database, 1 of them funded. They include Roivant Sciences, AbbVie and Gilead.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| roivant.com | 2014 | New York, United States | $1.3B | 662 | Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | |
| abbvie.com | 2012 | Chicago, United States | 8,667 | Biopharmaceutical research and drug development are conducted globally by AbbVie. | ||
| gilead.com | 1987 | Foster, United States | 4,267 | Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others |
Detailed competitors of Vertex Pharmaceuticals
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Vertex Pharmaceuticals
The website of Vertex Pharmaceuticals (vrtx.com) receives about 342.2K visits a month and ranks #151,023 among all websites worldwide, #4,689 in Biotechnology and Pharmaceuticals.
- Monthly visits342.2K
▲ 8% vs previous month
- Unique visitors125.4K
per month
- Global rank#151,023
among all websites
- Category rank#4,689
Health · Biotechnology and Pharmaceuticals
- Bounce rate45%
- Pages per visit2.6
- Average visit2 min 12 sec
- DevicesDesktop 60% · Mobile 40%
Websites whose visitors overlap most with Vertex Pharmaceuticals. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| pfizer.com | 100% | 1.9M | #24,984 | View details | |
| shire.com | 92% | 1.4K | #14,679,892 | View details | |
| novartis.com | 86% | 948.8K | #58,822 | View details | |
jobs.takeda.com | jobs.takeda.com | 78% | #185,912 | – | |
careers.lilly.com | careers.lilly.com | 73% | #60,411 | – | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 40 similar websites and full traffic analytics for Vertex Pharmaceuticals
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 40 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Pharmaceuticals & Distribution
3 companies that operate in the same segment as Vertex Pharmaceuticals (Pharmaceuticals & Distribution) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | 2014 | New York, New York, United States | USD 1.3 B | USD 8.26 M | 750 | |
Developer of pharmaceutical products for treating multiple diseases | 1980 | Thousand Oaks, California, United States | USD 33.23 B | 28,000 | ||
Biopharmaceutical research and drug development are conducted globally by AbbVie. | 2012 | Chicago, Illinois, United States | USD 61.16 B | 55,000 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Vertex Pharmaceuticals
Complete news archive for Vertex Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Vertex Pharmaceuticals
Vertex Pharmaceuticals was founded in 1989 and raised its 1st funding round 5 years after it was founded.
Vertex Pharmaceuticals is headquartered in United States.
Reshma Kewalramani is the CEO of Vertex Pharmaceuticals, as recorded in our data.
Vertex Pharmaceuticals has 6,100 employees.
Annual revenue of Vertex Pharmaceuticals is $12.07B as on Dec 31, 2025.
Vertex Pharmaceuticals was founded in 1989 in the United States. Operations focus on the biotechnology sector, where small molecule drugs are developed to address cystic fibrosis, viral diseases, inflammation, autoimmune conditions, cancer, and pain. Treatments such as IVACAFTOR and LUMACAFTORIVACAFTOR target the CFTR protein by enhancing channel opening and preventing misfolding. In 2022, annual revenues reached 8.93 billion, with net profit at 3.32 billion.
Vertex Pharmaceuticals's top competitors include Roivant Sciences, AbbVie and Gilead.
Vertex Pharmaceuticals offers Cystic Fibrosis Medicines, Kidney Disease Treatments, and Clinical Trial Programs.
Yes, Vertex Pharmaceuticals is publicly traded on NASDAQ under the ticker symbol VRTX.
Vertex Pharmaceuticals has made 5 acquisitions, including Alpine Immune Sciences, Crinetics, and Exonics.
Vertex Pharmaceuticals has 2 investors. Key investors include HHS, and Athyrium Capital Management.
Vertex Pharmaceuticals operates through Vertex Pharmaceuticals Ltd.